Can-Fite BioPharmaCANF
Market Cap: 18.5M
About: Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Employees: 5
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 0
98% more capital invested
Capital invested by funds: $536K [Q4 2023] → $1.06M (+$524K) [Q1 2024]
0.83% more ownership
Funds ownership: 0.87% [Q4 2023] → 1.7% (+0.83%) [Q1 2024]
11% less funds holding
Funds holding: 9 [Q4 2023] → 8 (-1) [Q1 2024]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Research analyst outlook
2 Wall Street Analysts provided 1 year price forecasts over the past 6 months
2 analyst ratings
EF Hutton Jason Kolbert | 170%upside $10 | Buy Initiated | 17 Jul 2024 |
HC Wainwright & Co. Vernon Bernardino | 385%upside $18 | Buy Reiterated | 9 May 2024 |
Financial journalist opinion
Based on 3 articles about CANF published over the past 30 days